Pulmonary hypertension. The 2022 ESC/ERS revised guidelines have redefined it. New evidence from ongoing and completed clinical trials have led to updates in diagnostic thresholds and treatment algorithms. New agents — some approved, others advancing through the pipeline — promise improved efficacy and safety for a variety of patients. What does it all mean to practitioners in the clinic?
Join Dr. Catherine Simpson, from the Division of Pulmonary and Critical Care at the Johns Hopkins University School of Medicine, as she discusses how applying these new findings can improve patient outcomes in this issue of ePulmonology Review.
Describe how changes to the 2022 ESC/ERS guidelines, including the revised classification of pulmonary hypertension and lowering the threshold for defining it, may impact clinical practice.
Discuss how the revised 2022 ESC/ERS guidelines recommendation for inhalation therapy with treprostinil can affect management of PH due to interstitial lung disease (ILD).
Assistant Professor of Medicine,
Division of Pulmonary and Critical Care,
Johns Hopkins School of Medicine
Professor of Medicine, Epidemiology and Environmental Health Sciences
Johns Hopkins University School of Medicine
Senior Clinic Nurse Coordinator
Johns Hopkins Medicine
0.5 hour Physicians
0.5 contact hour Nurses
Launch date: February 9, 2024
Expiration date: February 8, 2026